Filing Details

Accession Number:
0001193805-20-000087
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-31 16:17:49
Reporting Period:
2020-01-29
Accepted Time:
2020-01-31 16:17:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661998 Homology Medicines Inc. FIXX () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1009258 Deerfield Management Company, L.p. (Series C) 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1010823 L.p. Mgmt Deerfield 780 Third Avenue
37Th Floor
New York NY 10017
No No Yes Yes
1301041 Deerfield Partners, L.p. 780 Third Avenue
37Th Floor
New York NY 10017
No No Yes Yes
1352546 E James Flynn 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1603333 Deerfield Private Design Fund Iii, L.p. 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1610540 Deerfield Mgmt Iii, L.p. 780 Third Avenue, 37Th Floor
New York NY 10017
No No Yes Yes
1646981 Deerfield Healthcare Innovations Fund, L.p. 780 Third Avenue
37Th Floor
New York NY 10017
No No Yes Yes
1665736 Deerfield Mgmt Hif, L.p. 780 Third Avenue
37Th Floor
New York NY 10017
No No Yes Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-01-29 8,857 $15.45 509,970 No 4 S Indirect Through Deerfield Partners, L.P.
Common Stock Disposition 2020-01-30 509,970 $15.45 0 No 4 S Indirect Through Deerfield Partners, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Through Deerfield Partners, L.P.
No 4 S Indirect Through Deerfield Partners, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,766,106 Indirect Through Deerfield Healthcare Innovations Fund, L.P.
Common Stock 2,321,199 Indirect Through Deerfield Private Design Fund III, L.P.
Footnotes
  1. The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.40 to $15.51, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. (collectively with Fund III and Deerfield Partners, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P.
  3. In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.